Alvotech, a global biotech company focused on biosimilar medicines, has announced the acquisition of Xbrane Biopharma AB’s R&D operations and the biosimilar candidate XB003. The deal, valued at approximately SEK 275 million (USD 27 million), strengthens Alvotech’s development capabilities and marks its entry into
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech have announced the availability of SELARSDI (ustekinumab-aekn) in the United States. This biosimilar to Stelara (ustekinumab) is approved for multiple indications, including psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric
Alvotech, a global biotech company focused on biosimilars, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration (FDA) has accepted their Biologics License Applications (BLAs) for AVT05. The proposed biosimilar
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
